Hormonal and pathologic changes after chemoablation of testes with hypertonic saline solution as a treatment method alternative to orchiectomy in patients with hormone sensitive metastatic prostatic cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 2, 2011, Pages 212-217

  Emir, Levent ^a   Sunay, Melih ^a   Yalbuzdaǧ, Okan ^a   Karakaya, Yakup ^a   Erol, Demokan ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Castration; Chemoablation; Hypertonic saline; Rats

Indexed keywords

CHORIONIC GONADOTROPIN; SODIUM CHLORIDE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HORMONE SENSITIVITY; MALE; NONHUMAN; ORCHIECTOMY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE METASTASIS; RAT; TESTIS; TESTOSTERONE BLOOD LEVEL; TUMOR ABLATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NECROSIS; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SALINE SOLUTION, HYPERTONIC; TESTIS; TESTOSTERONE; TIME FACTORS;

EID: 79952040628     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.12.021     Document Type: Article

References (11)

1. Tena-Sempere M.L., Pinilla L., Aguilar E. Follicle-stimulating hormone and luteinizing hormone secretion in male rats orchiectomized or injected with ethylene dimethane sulfonate. Endocrinology 1993, 133:1173-1181.
2. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance, series: Interpreting trends in prostate cancer. Part 1. Evidence of effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999, 91:1017-1021.
3. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
4. Lin B.J., Chen K.K., Chen M.T., et al. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogens in the management of metastatic prostatic cancer. Urology 1994, 43:834-837.
5. Riba L.W. Subcapsular castration for carcinoma of prostate. J Urol 1942, 48:384-387.
6. McDonald J.H., Calams J.A. Extraparenchymal Leydig-like cells: Observations following subcapsular orchiectomy. J Urol 1959, 82:145-147.
7. Chapman J.P. Comparison of testosterone and LH values in subcapsular vs total orchiectomy patients. Urology 1987, 30:27-28.
8. Schally A.V., Arimura A., Baba Y., et al. Isolation and Properties of the FSH and LH releasing hormone. Biochem Biophys Res Commun 1971, 43:393-399.
9. Auclair C., Kelly P.A., Labrie F., et al. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent LHRH agonist or human chorionic gonadotropin. Biochem Biophys Res Commun 1977, 76:855-862.
10. Thompson I.M., Zeidman E.J., Rodriguez F.R. Sudden death due to disease flare with LHRH agonist therapy for carcinoma of prostate. J Urol 1990, 144:1479-1480.
11. Baccon-Gibod L. The prevention of LHRH induced disease flares in patients with metastatic carcinoma of the prostate. Prog Clin Biol Res 1990, 359:125-129.